The new operations provide Kendle’ customers (mainly global biopharmaceutical players) access to additional patient populations while strengthening the company’s position as a global clinical development partner.
Candace Kendle, Chairman and CEO, said: Kendle is one of the few truly global providers providers offering comprehensive Phase I-IV solutions to meet the needs of the world’s biopharmaceutical industry,
Our expanded presence in the Asia/Pacific region enhances opportunities for patient access, creates efficiencies in the clinical development process and overall strengthens Kendle’s ability to foster global strategic alliances with the leading companies in the biopharmaceutical industry, he added.
Kendle is currently located in Beijing, Hong Kong and Shanghai, China; New Delhi and Ahmedabad, India; Singapore; and Sydney and Melbourne, Australia.